Anti-TNF therapy: Past, present and future

International Immunology

Volumn 27, Issue 1, 2015, Pages 55-62

  Monaco, Claudia ^a   Nanchahal, Jagdeep ^a   Taylor, Peter ^a   Feldmann, Marc ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti cytokine therapy; Atherosclerosis; Fibrosis; Fractures; Rheumatoid arthritis

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG INDICATION; DRUG MECHANISM; DUPUYTREN CONTRACTURE; FRAGILITY FRACTURE; HUMAN; NONHUMAN; POSTOPERATIVE COGNITIVE DYSFUNCTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; HUMANS; IMMUNOTHERAPY; INFLIXIMAB; MOLECULAR TARGETED THERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922439718     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxu102     Document Type: Article

References (61)

1. Fong, Y., Tracey, K. J., Moldawer, L. L. et al. 1989. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170:1627.
2. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N. and Williamson, B. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72:3666.
3. Naylor, M. S., Stamp, G. W., Foulkes, W. D., Eccles, D. and Balkwill, F. R. 1993. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Invest. 91:2194.
4. Xanthoulea, S., Pasparakis, M., Kousteni, S. et al. 2004. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. 200:367.
5. McCann, F. E., Perocheau, D. P., Ruspi, G. et al. 2014. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals an immunoregulatory role for tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheum. 66:2728.
6. Bottazzo, G. F., Pujol-Borrell, R., Hanafusa, T. and Feldmann, M. 1983. Hypothesis: role of aberrant HLA-DR expression and antigen presentation in the induction of endocrine autoimmunity. Lancet ii:1115.
7. Maini, R. N., Bryceson, A. D., Wolstencroft, R. A. and Dumonde, D. C. 1969. Lymphocyte mitogenic factor in man. Nature 224:43.
8. Feldmann, M. and Basten, A. 1972. Specific collaboration between T and B lymphocytes across a cell impermeable membrane in vitro. Nat. New Biol. 237:13.
9. Buchan, G. S., Barrett, K., Fujita, T., Taniguchi, T., Maini, R. N. and Feldmann, M. 1988. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin 2, IL-2 receptor and interferon γ. Clin. Exp. Immunol. 71:295.
10. Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N. and Feldmann, M. 1988. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 73:449.
11. Feldmann, M., Brennan, F. M. and Maini, R. N. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397.
12. Brennan, F. M., Chantry, D., Jackson, A., Maini, R. N. and Feldmann, M. 1989. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244.
13. Haworth, C., Brennan, F. M., Chantry, D., Turner, M., Maini, R. N. and Feldmann, M. 1991. Expression of granulocytemacrophage colony-stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur. J. Immunol. 21:2575.
14. Williams, R. O., Feldmann, M. and Maini, R. N. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collageninduced arthritis. Proc. Natl Acad. Sci. USA 89:9784.
15. Beutler, B., Milsark, I. W. and Cerami, A. C. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869.
16. Elliott, M. J., Maini, R. N., Feldmann, M. et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36:1681.
17. Elliott, M. J., Maini, R. N., Feldmann, M. et al. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125.
18. Elliott, M. J., Maini, R. N., Feldmann, M. et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105.
19. Maini, R. N., Breedveld, F. C., Kalden, J. R. et al. 1998. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1552.
20. Lipsky, P. E., van der Heijde, D. M. F. M., St Clair, E. W. et al. 2000. Infliximab and methotrexate in the treatment of RA. N. Engl. J. Med. 343:1594.
21. Charles, P., Elliott, M. J., Davis, D. et al. 1999. Regulation of cytokines and acute phase proteins following TNFα blockade in rheumatoid arthritis. J. Immunol. 163:1521.
22. Taylor, P. C., Peters, A. M., Paleolog, E. et al. 2000. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43:38.
23. Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D. et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:253.
24. Weinblatt, M. E., Keystone, E. C., Furst, D. E. et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48:35.
25. Combe, B., Codreanu, C., Fiocco, U. et al. 2009. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann. Rheum. Dis. 68:1146.
26. Keystone, E., Emery, P., Peterfy, C. G. et al. 2009. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann. Rheum. Dis. 68:216.
27. Genovese, M. C., Becker, J. C., Schiff, M. et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353:1114.
28. Emery, P., Keystone, E., Tony, H. P. et al. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67:1516.
29. Shepard, H. M., Jin, P., Slamon, D. J., Pirot, Z. and Maneval, D. C. 2008 Herceptin. Handb. Exp. Pharmacol. 181:183.
30. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335.
31. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457.
32. Gregory, A. P., Dendrou, C. A., Attfield, K. E. et al. 2012. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488:508.
33. Charles, P. J., Smeenk, R. J., De Jong, J., Feldmann, M. and Maini, R. N. 2000. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43:2383.
34. Aringer, M., Graninger, W. B., Steiner, G. and Smolen, J. S. 2004. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50:3161.
35. Abraham, E., Anzueto, A., Gutierrez, G. et al. 1998. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351:929.
36. Hussell, T., Pennycook, A. and Openshaw, P. J. 2001. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31:2566.
37. Wilson, M. R., Choudhury, S. and Takata, M. 2005. Pulmonary inflammation induced by high-stretch ventilation is mediated by tumor necrosis factor signaling in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L599.
38. Moller, J. T., Cluitmans, P., Rasmussen, L. S. et al. 1998. Longterm postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 351:857.
39. Wan, Y., Xu, J., Ma, D., Zeng, Y., Cibelli, M. and Maze, M. 2007. Postoperative impairment of cognitive function in rats: a possible role for cytokine-mediated inflammation in the hippocampus. Anesthesiology 106:436.
40. Terrando, N., Rei Fidalgo, A., Vizcaychipi, M. et al. 2010. The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit. Care 14:R88.
41. Terrando, N., Monaco, C., Ma, D., Foxwell, B. M., Feldmann, M. and Maze, M. 2010. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc. Natl Acad. Sci. USA 107:20518.
42. Hurst, L. C., Badalamente, M. A., Hentz, V. R. et al. 2009. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N. Engl. J. Med. 361:968.
43. Verjee, L. S., Midwood, K., Davidson, D., Eastwood, M. and Nanchahal, J. 2010. Post-transcriptional regulation of alphasmooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells. J. Cell. Physiol. 224:681.
44. Verjee, L. S., Verhoekx, J. S. N., Chan, J. K. K. et al. 2013. Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc. Natl Acad. Sci. USA 110:E928.
45. Mundi, S., Pindiprolu, B., Simunovic, N. and Bhandari, M. 2014. Similar mortality rates in hip fracture patients over the past 31 years. Acta Orthop. 85:54.
46. Glass, G. E., Chan, J. K., Freidin, A., Feldmann, M., Horwood, N. J. and Nanchahal, J. 2011. TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc. Natl Acad. Sci. USA 108:1585.
47. Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A. and Willerson, J. T. 2003. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133.
48. Mann, D. L., McMurray, J. J., Packer, M. et al. 2004. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594.
49. Jacobsson, L. T., Turesson, C., Gülfe, A. et al. 2005. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32:1213.
50. Wolfe, F. and Michaud, K. 2004. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. 116:305.
51. Monaco, C., Gregan, S. M., Navin, T. J., Foxwell, B. M., Davies, A. H. and Feldmann, M. 2009. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 120:2462.
52. Smith, A., ed. 1776. An Inquiry Into the Nature and Cause of the Wealth of Nations. W. Strahan and T. Cadell, London, UK.
53. Goekoop-Ruiterman, Y. P., de Vries-Bouwstra, J. K., Allaart, C. F. et al. 2005. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52:3381.
54. Ban der Bijl, A. E., Goekoop-Ruiterman, Y. P., de Vries-Bouwstra, J. K. et al. 2007. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 56:2129.
55. Genovese, M. C., Cohen, S., Moreland, L. et al. 2004. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50:1412.
56. Weinblatt, M., Schiff, M., Goldman, A. et al. 2007. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66:228.
57. Miotla, J., Maciewicz, R., Kendrew, J., Feldmann, M. and Paleolog, E. 2000. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Invest. 80:1195.
58. Vanniasinghe, A. S., Manolios, N., Schibeci, S. et al. 2014. Targeting fibroblast-like synovial cells at sites of inflammation with peptide targeted liposomes results in inhibition of experimental arthritis. Clin. Immunol. 151:43.
59. Foulquier, C., Sebbag, M., Clavel, C. et al. 2007. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 56:3541.
60. Maresz, K. J., Hellvard, A., Sroka, A. et al. 2013. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog. 9:1.
61. Su, L. F., Han, A., McGuire, H. M., Furman, D., Newell, E. W. and Davis, M. M. 2013. The promised land of human immunology. 2014. Cold Spring Harb. Symp. Quant. Biol. 78:203.